ARIAD to Present Preclinical Data at AACR Annual Meeting

Loading...
Loading...
ARIAD Pharmaceuticals, Inc.
ARIA
today announced its schedule of preclinical data presentations to be made at the American Association for Cancer Research (AACR) Annual Meeting 2013, taking place Saturday, April 6 through Wednesday, April 10, 2013, in Washington. Listed below are the details of presentations at AACR that describe ARIAD's product candidates. There will be four presentations of data on ARIAD's targeted therapies, Iclusig™ (ponatinib) and AP26113; and one invited talk: Title: Ponatinib is a highly potent inhibitor of activated variants of RET found in MTC and NSCLC Date & Time: Monday, April 8, 1:00–5:00 p.m. (Poster) Abstract: #2084 Location: Hall A-C, Poster Section 38 Title: Ponatinib potently inhibits the activity of mutant variants of FGFR commonly found in endometrial, lung and other cancers Date & Time: Monday, April 8, 1:00–5:00 p.m. (Poster) Abstract: #2083 Location: Hall A-C, Poster Section 38 Title: Ponatinib, a pan-BCR-ABL inhibitor, potently inhibits key activating and drug-resistant KIT mutants found in GIST Date & Time: Tuesday, April 9, 8:00 a.m.–12:00 p.m. (Poster) Abstract: #3394 Location: Hall A-C, Poster Section 42 Title: Design and development of ponatinib, a pan-BCR-ABL inhibitor for CML Date & Time: Tuesday, April 9, 9:30–10:00 a.m. (Major symposium) Presentation: #SY19-04 Location: Salon A-B, East Hall Title: AP26113 possesses pan-inhibitory activity versus crizotinib-resistant ALK mutants and oncogenic ROS1 fusions Date & Time: Wednesday, April 10, 8:00 a.m.–12:00 p.m. (Poster) Abstract: #5655 Location: Hall A-C, Poster Section 42
Loading...
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...